Introduction

Follicular lymphoma remains a common yet complex malignancy. This disease often follows an indolent course but frequently results in repeated relapses. Consequently, patients often experience progressively shorter responses with each successive line of therapy. Recently, odronextamab follicular lymphoma treatment has emerged as a promising chemo-free approach for relapsed or refractory cases. This bispecific antibody specifically targets CD20 and CD3 to harness the patient's own immune system.

Odronextamab Follicular Lymphoma Trial Efficacy

The clinical development of odronextamab centers on the pivotal ELM-1 and ELM-2 studies. These trials investigated its safety and anti-tumor activity in heavily pretreated patients. Specifically, the phase II ELM-2 trial reported an objective response rate (ORR) of approximately 80% in the follicular lymphoma cohort. Furthermore, over 70% of these patients achieved a complete response. These durable results led to its conditional approval by the European Medicines Agency (EMA). Moreover, researchers are now evaluating its performance in earlier lines of therapy via the OLYMPIA trial program.

Mechanism of Action and Safety Considerations

The therapeutic mechanism involves simultaneously binding to CD20 on malignant B-cells and CD3 on T-cells. This dual engagement facilitates potent T-cell-mediated cytotoxicity against the lymphoma cells. Although the efficacy is high, clinicians must manage specific adverse events like cytokine release syndrome (CRS). Most cases of CRS occur early during treatment and are generally manageable with step-up dosing and prophylaxis. Additionally, ongoing studies like OLYMPIA-1 and OLYMPIA-5 are exploring combinations with agents like lenalidomide to improve outcomes further. Therefore, odronextamab represents a significant shift toward precision immunotherapy in hematological oncology.

Frequently Asked Questions

What makes odronextamab different from traditional rituximab?

Unlike rituximab, which is a monoclonal antibody, odronextamab is a bispecific antibody. It does not just mark cells for destruction; it actively pulls T-cells into direct contact with cancer cells to trigger a kill response.

Is odronextamab used as a first-line treatment?

Currently, regulatory approval focuses on relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. However, ongoing phase III trials are investigating its use in earlier and frontline settings.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Garcia-Sancho AM et al. Odronextamab: a bispecific antibody for follicular lymphoma. Expert Opin Investig Drugs. 2026 Jun 13. doi: 10.1080/13543784.2026.2689652. PMID: 42287116.


2. European Medicines Agency (EMA). Ordspono (odronextamab): Summary of Product Characteristics. 2024.


3. Kim TM et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma (ELM-2). Annals of Oncology. 2024.